SCYNEXIS Inc. | Mutual Funds
Mutual Funds that own SCYNEXIS Inc.
Federated Kaufmann Fund
5,585,000
11.92%
2,260,000
0.11%
06/29/2018
Vanguard Total Stock Market Index Fund
1,198,544
2.56%
0
0%
07/31/2018
Federated Kaufmann Small Cap Fund
1,144,000
2.44%
344,000
0.1%
06/29/2018
Vanguard Extended Market Index Fund
543,698
1.15%
2,075
0%
07/31/2018
Fidelity Spartan Extended Market Index Fund
338,656
0.72%
0
0%
07/31/2018
Bridgeway Ultra Small Company Market Fund
150,000
0.32%
0
0.05%
12/31/2017
Federated Kaufmann II Fund
139,400
0.3%
56,000
0.1%
06/29/2018
iShares Micro Cap ETF
122,653
0.26%
0
0.01%
09/06/2018
Fidelity Nasdaq Composite Index
74,353
0.16%
0
0%
07/31/2018
Fidelity Spartan Total Market Index Fund
57,121
0.12%
0
0%
07/31/2018
| Address |
1 Evertrust Plaza
Jersey City New Jersey 07302
United States
|
|
Employees
|
- |
| Website |
http://www.scynexis.com |
| Updated |
07/08/2019 |
| SCYNEXIS, Inc. engages in the development and commercialization of novel anti-infectives, which addresses the significant unmet therapeutic needs. It develops a novel oral and intravenous drug for several fungal infections, including serious and life-threatening invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. |
